What are the alternatives to pregabalin (Lyrica) for treating neuropathic pain and epilepsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternatives to Pregabalin for Neuropathic Pain and Epilepsy

For neuropathic pain, amitriptyline and lamotrigine are reasonable first-line alternatives to pregabalin, with gabapentin as another option, though the choice depends on the specific type of neuropathic pain being treated. 1

First-Line Alternatives for Neuropathic Pain

Tricyclic Antidepressants

  • Amitriptyline (75 mg at bedtime) is a reasonable first-line alternative that has demonstrated superiority in lowering daily pain ratings and improving global functioning in neuropathic pain conditions. 1
  • In one comparative trial, amitriptyline 75 mg/day was significantly more effective than placebo for neuropathic pain, while pregabalin was not. 2
  • The standard treatment for neuropathic pain associated with diabetes or post-herpetic neuralgia is a tricyclic antidepressant, with gabapentin as an alternative. 2
  • Nortriptyline is another tricyclic option, though it has shown negative results in some conditions like chemotherapy-induced neuropathy. 1

Anticonvulsants

  • Lamotrigine is a reasonable first-line alternative that can reduce daily pain ratings and cold-induced pain, though only 44% of patients achieve a good clinical response. 1
  • Gabapentin is a viable alternative with a similar mechanism to pregabalin but has not been as extensively studied for certain neuropathic pain conditions, though it has proven effective in other forms of neuropathic pain. 1
  • Gabapentin has a lower risk of drug-drug interactions compared to carbamazepine, making it suitable for patients on multiple medications. 2
  • Carbamazepine and phenytoin may be considered as second-line treatments, though their usefulness is not well established. 1

Important Caveats About Neuropathic Pain Types

Conditions That May Be Refractory to Standard Treatments

  • HIV-associated neuropathy appears relatively refractory to first-line treatments including amitriptyline, gabapentin, and pregabalin, with multiple negative trials reported. 1
  • Chemotherapy-induced peripheral neuropathy has shown no evidence of efficacy with nortriptyline, amitriptyline, or gabapentin in three randomized controlled trials. 1
  • Lumbosacral radiculopathy may be relatively refractory to existing first- and second-line medications including nortriptyline, morphine, and pregabalin. 1
  • These findings suggest that efficacy in one neuropathic pain condition (like diabetic neuropathy or postherpetic neuralgia) cannot be automatically extrapolated to other types. 1

Alternatives for Epilepsy

Partial Epilepsy

  • Carbamazepine monotherapy is the first-line treatment for partial epilepsy. 2
  • Gabapentin monotherapy is an alternative given its lower risk of drug-drug interactions. 2
  • For refractory partial epilepsy inadequately controlled by combination therapy, pregabalin offers nothing new compared to several other available antiepileptics. 2

Additional Treatment Options for Specific Conditions

Central Poststroke Pain

  • Amitriptyline and lamotrigine are reasonable first-line pharmacological treatments. 1
  • Pregabalin, gabapentin, carbamazepine, or phenytoin may be considered as second-line treatments. 1
  • Interprofessional pain management is probably useful in conjunction with pharmacotherapy. 1

Erythromelalgia (if relevant to neuropathic pain context)

  • Gabapentin showed improvement in all 16 patients surveyed, though none achieved remission. 1
  • Pregabalin improved symptoms in two case reports, including one patient who had not responded to gabapentin. 1
  • Amitriptyline (oral and topical formulations) has been effective in case reports. 1

Key Pharmacological Differences

Gabapentin vs Pregabalin

  • Both medications have nearly identical adverse effect profiles, including dizziness, somnolence, peripheral edema, and weight gain. 3
  • Pregabalin has more predictable absorption and linear pharmacokinetics compared to gabapentin. 3, 2
  • Maximum dose of gabapentin is 3600 mg/day compared to 600 mg/day for pregabalin. 3
  • Gabapentin is NOT a suitable substitution therapy for pregabalin use disorder, as patients experience intense craving and distress despite high doses. 4

Practical Algorithm for Choosing Alternatives

  1. Start with amitriptyline 75 mg at bedtime for most neuropathic pain conditions (diabetic neuropathy, postherpetic neuralgia), unless contraindicated by cardiac issues or anticholinergic sensitivity. 1, 2

  2. Consider lamotrigine if tricyclics are contraindicated or poorly tolerated, with slow titration to minimize side effects. 1

  3. Use gabapentin as an alternative when drug-drug interactions are a concern or for patients who prefer a medication with lower interaction potential. 1, 2

  4. Avoid standard first-line treatments in HIV neuropathy, chemotherapy-induced neuropathy, and lumbosacral radiculopathy, as these conditions may require alternative approaches or spinal cord stimulation. 1

  5. For partial epilepsy, use carbamazepine monotherapy as first-line, with gabapentin as an alternative. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pregabalin: new drug. Very similar to gabapentin.

Prescrire international, 2005

Guideline

Pregabalin Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.